HER2 Breast Cancer

The panelists discuss clinical experience with the HER2CLIMB regimen, including main adverse effects.

The experts have a detailed conversation on the HER2CLIMB trial, including third-line treatment options and the importance of having a detailed and balanced conversation with patients.

Experts discuss the treatment considerations for HER2+ metastatic breast cancer and provide an overview of the DESTINY-Breast01 trial.

The experts discuss a case presentation of a 63-year-old woman with relapsed HER2+ metastatic breast cancer and discuss rate of relapse in this patient population.

Experts in breast cancer review clinical cases, discuss individualized treatment options and key clinical trials.

Debu Tripathy, MD, discusses the role that margetuximab will have in the field of HER2-positive metastatic breast cancer now that it is approved by the FDA.

In an interview with Targeted Oncology, Erika P. Hamilton, MD, explained how hormone receptor status in patients with HER2-positive breast cancer was affected by treatment with the HER2CLIMB regimen of tucatinib plus trastuzumab and capecitabine.

Positive efficacy and safety results observed with the proposed trastuzumab biosimilar, EG12014 in HER2-positive early breast cancer, has led the developer to plan regulatory filings in the United States, Europe, and China.

In an interview with Ecaterina Ileana Dumbrava, MD, discussed the ongoing study of BDC-1001 alone and in combination with an immune checkpoint inhibitor for the treatment of HER2-positive breast cancer and other solid tumors.

In an interview with Targeted Oncology, Joyce O’Shaughnessy, MD, chair of Breast Cancer Research and chair of Breast Cancer Prevention Research at Baylor-Sammons Cancer Center of Texas Oncology, discussed the CONTESSA stusy of tesetaxel with a reduced dose of capecitabine versus capecitabine alone in patients with HR-positive, HER2-negative breast cancer.

Debu Tripathy, MD, discusses escalation and de-escalation of treatment in patients with HER2-positive breast cancer with HER2-targeted agents and chemotherapy.

Ecaterina Ileana Dumbrava, MD, discusses the rationale for combing BDC-1001, a HER2-targeting TLR7/8 immune-stimulating antibody conjugate with an immune checkpoint inhibitor.

During a Targeted Oncology Case-Based Peer Perspectives event, Sara M. Tolaney, MD, MPH, discussed therapies available for the treatment of a 42-year-old woman with HER2-positive breast cancer.

Final analysis of data on HER2-positive disease presented at the 2020 San Antonio Breast Cancer Symposium from experts in the field of breast oncology.

Experts in breast oncology discuss the evolving role of trastuzumab deruxtecan for metastatic HER2-positive breast cancer.

Hatem Soliman, MD, reviews statistically significant data from the PERTAIN study, presented at the 2020 San Antonio Breast Cancer Symposium.

Experts in breast oncology discuss their real-world experience with trastuzumab emtansine (T-DM1) for patients with advanced HER2-positive breast cancer.

Analysis from the ALTTO (BIG 2-06) trial and the relationship between a short or long disease-free interval and overall survival.

Updated findings on the use of neratinib for HER2+ breast cancer from the 2020 SABCS Virtual Symposium.

Updated findings on the use of neratinib for HER2+ breast cancer from the 2020 SABCS Virtual Symposium.

A discussion on the importance of prognostic tools for early stage breast cancer.

Hatem Soliman, MD, discusses data presented at the 2020 SABCS for patients with HER2-enriched subtypes that showed benefit from CDK4/6 inhibition.

Andrew Seidman, MD, provides insight on clinical sequencing for patients with advanced HER2-positive breast cancer.

Experts in breast oncology discuss the evolving landscape in early stage and metastatic HER2-positive breast cancer.

A review of key relevant data on HER2-positive breast cancer from the 2020 SABCS Virtual Symposium.